- Home
- AKA vs MGNX Comparison
AKA vs MGNX Comparison
Compare AKA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- MGNX
- Stock Information
- Founded
- AKA 2018
- MGNX 2000
- Country
- AKA United States
- MGNX United States
- Employees
- AKA N/A
- MGNX N/A
- Industry
- AKA Catalog/Specialty Distribution
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- MGNX Health Care
- Exchange
- AKA Nasdaq
- MGNX Nasdaq
- Market Cap
- AKA 110.4M
- MGNX 99.7M
- IPO Year
- AKA 2021
- MGNX 2013
- Fundamental
- Price
- AKA $10.59
- MGNX $1.58
- Analyst Decision
- AKA Strong Buy
- MGNX Hold
- Analyst Count
- AKA 3
- MGNX 5
- Target Price
- AKA $24.33
- MGNX $3.25
- AVG Volume (30 Days)
- AKA 3.3K
- MGNX 620.9K
- Earning Date
- AKA 08-06-2025
- MGNX 08-14-2025
- Dividend Yield
- AKA N/A
- MGNX N/A
- EPS Growth
- AKA N/A
- MGNX N/A
- EPS
- AKA N/A
- MGNX N/A
- Revenue
- AKA $598,107,000.00
- MGNX $165,495,000.00
- Revenue This Year
- AKA $6.60
- MGNX N/A
- Revenue Next Year
- AKA $4.14
- MGNX N/A
- P/E Ratio
- AKA N/A
- MGNX N/A
- Revenue Growth
- AKA 7.67
- MGNX 303.47
- 52 Week Low
- AKA $7.00
- MGNX $0.99
- 52 Week High
- AKA $32.25
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- AKA 41.02
- MGNX 50.75
- Support Level
- AKA $11.11
- MGNX $1.43
- Resistance Level
- AKA $11.38
- MGNX $1.67
- Average True Range (ATR)
- AKA 0.41
- MGNX 0.12
- MACD
- AKA -0.07
- MGNX -0.01
- Stochastic Oscillator
- AKA 4.25
- MGNX 52.63
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.